Page last updated: 2024-09-04

ptk 787 and semaxinib

ptk 787 has been researched along with semaxinib in 2 studies

Compound Research Comparison

Studies
(ptk 787)
Trials
(ptk 787)
Recent Studies (post-2010)
(ptk 787)
Studies
(semaxinib)
Trials
(semaxinib)
Recent Studies (post-2010) (semaxinib)
50148031218

Protein Interaction Comparison

ProteinTaxonomyptk 787 (IC50)semaxinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Dihydrofolate reductaseHomo sapiens (human)2.4
Dihydrofolate reductaseMus musculus (house mouse)2.4
Epidermal growth factor receptorHomo sapiens (human)3.592
Platelet-derived growth factor receptor betaMus musculus (house mouse)4.05
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.084
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.17
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)0.5
Platelet-derived growth factor receptor betaHomo sapiens (human)2.3563
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.365
Fibroblast growth factor receptor 1Homo sapiens (human)4.865
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)0.5
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)3.89
Dihydrofolate reductasePneumocystis carinii2.4
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.7648
Fibroblast growth factor receptor 2Homo sapiens (human)5
Fibroblast growth factor receptor 4Homo sapiens (human)5
Fibroblast growth factor receptor 3Homo sapiens (human)5
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)4.05
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.275
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)1.04
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.0999
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)1.04
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.16
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.2
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)0.068
1,25-dihydroxyvitamin D-3 receptor Sus scrofa domesticus (domestic pig)1.04
Dihydrofolate reductaseRattus norvegicus (Norway rat)2.4
ALK tyrosine kinase receptorHomo sapiens (human)1.505

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B1
Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J1

Other Studies

2 other study(ies) available for ptk 787 and semaxinib

ArticleYear
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
    Journal of medicinal chemistry, 2000, Jun-15, Volume: 43, Issue:12

    Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1

2000
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
    Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26

    Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor

2002